

Subject:

FW: Amryt announces positive top line results from Phase 3 clinical trial



## EB Research Update

Hi First name,

Following on from our last email update a couple of weeks ago we are delighted to announce some good news:

### **AMRYT ANNOUNCES POSITIVE TOP LINE RESULTS FROM PIVOTAL PHASE 3 "EASE" TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA**

Ireland was among the locations where the study was performed. There is still a long way to go to get to market but really positive news coming from the world of research.

- Primary endpoint met with statistical significance (p-value = 0.013)
  - FILSUVEZ® demonstrated a good safety profile
- EASE is the first Phase 3 trial to demonstrate a statistically significant increase in speed of wound healing in Epidermolysis Bullosa
- Rolling US regulatory submissions already underway with FDA with priority review request planned
- EU regulatory submission planned with request for accelerated assessment
- FILSUVEZ®, a topical therapeutic gel, has the potential to be the first treatment approved for Epidermolysis Bullosa



See the full press release here:

<http://bit.ly/ap090920>

Further details on the results of the clinical trial will be available in November.

Best regards,

Sinéad

*Research Manager*

[Privacy Policy](#) | [Unsubscribe](#)

[DEBRA Ireland](#)

8 Clanwilliam Terrace, Grand Canal Quay, Dublin 2 D02 R240